| 0.4098 -0.026 (-5.92%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.53 | 1-year : | 0.62 |
| Resists | First : | 0.45 | Second : | 0.53 |
| Pivot price | 0.42 |
|||
| Supports | First : | 0.39 | Second : | 0.34 |
| MAs | MA(5) : | 0.43 |
MA(20) : | 0.41  |
| MA(100) : | 0.72 |
MA(250) : | 1.58 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 71.9 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 3.52 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMMP ] has closed above bottom band by 23.5%. Bollinger Bands are 91.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.44 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.41 - 0.41 | 0.41 - 0.41 |
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Fri, 17 Jul 2026
IMMP SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Fri, 17 Jul 2026
Why Is This Beaten-Down Biotech Surging 150% In Pre-Market Today? - Stocktwits
Wed, 15 Jul 2026
Immutep Granted New US Patent for Cancer Treatment Methods - Moomoo
Tue, 14 Jul 2026
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor - GlobeNewswire
Tue, 14 Jul 2026
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC Filing - Form 6-K - Stock Titan
Tue, 14 Jul 2026
Citizens maintains Immutep stock rating on cash analysis - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 147 (M) |
| Shares Float | 143 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 3,900 (K) |
| Shares Short P.Month | 4,350 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | 0 % |
| Operating Margin | -763.8 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -61.9 % |
| Qtrly Rev. Growth | 91.5 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 7.62 |
| Price to Cash Flow | -0.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|